251 286 - Biotech Bayern
251 286 - Biotech Bayern
251 286 - Biotech Bayern
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Contact:<br />
Dr. Bettina Kipp<br />
Grillparzerstr. 14<br />
D-81675 München<br />
Phone: +49 (0) 89 2000 14210<br />
Fax: +49 (0) 89 2000 14279<br />
E-Mail: Bettina.Kipp@curacyte.com<br />
Internet: www.curacyte.com<br />
Contact:<br />
Dr. Heike Wöhling<br />
Haringstr. 19<br />
D-85635 Höhenkirchen<br />
Phone: +49 (0) 8102 8950 6<br />
Fax: +49 (0) 8102 8950 89<br />
E-Mail: info@dabio.com<br />
Internet: www.dabio.com<br />
Contact:<br />
Olaf Lamberz<br />
Zielstattstr. 48<br />
D-81379 München<br />
Phone: +49 (0) 89 7808-442<br />
Fax: +49 (0) 89 7808-288<br />
E-Mail: olaf_lamberz@sankyo-pharma.com<br />
Internet: www.sankyo-pharma.com<br />
56<br />
Curacyte AG<br />
BIOTECH THERAPEUTICS & DIAGNOSTICS<br />
Keywords: Drug Development, Small Molecules, Cardiovascular Diseases,<br />
Multi organ failure<br />
Curacyte AG is a research-based biopharmaceutical company dedicated to the<br />
discovery and development of hospital therapeutics for acute and critical care<br />
conditions.<br />
Curacyte's pipeline comprises projects from discovery to late-stage clinical<br />
development. Hemoximer (PHP, pyridoxalated hemoglobin polyoxyethylene) is<br />
the company's most advanced drug candidate and is about to enter a pivotal<br />
phase III trial as treatment for patients suffering from distributive shock.<br />
DABIO Gesellschaft für Auftragsforschung mbH<br />
CRO<br />
Keywords: Drug Development, Allergy, Cardiovascular Diseases, Dermatology,<br />
Hepatology, Oncology, Ophtalmology, Pain, Respiratory Diseases, Rheumatology<br />
DABIO is a privately owned, independent CRO founded in 1994. DABIO provides<br />
a wide range of cost effective services as an external R&D partner for pharma<br />
and biotech companies. DABIO's qualified staff has many years of industrial<br />
experiences. We provide full or partial services for clinical trials phase II-IV, post<br />
marketing surveillances and phase I trials in cooperation with different partners.<br />
Our services include concept and protocol development, trial administration<br />
and monitoring, data management, biometrics and medical writing according<br />
to ICH-GCP guidelines and national law. DABIO provides special services such as<br />
pharmacoeconomics, expert reports, publications, organization of meetings and<br />
online solutions for EDC.<br />
Daiichi Sankyo Europe GmbH<br />
PHARMA & CHEMICAL INDUSTRY<br />
Keywords: Drug Development, Antibiotics, Bone / Joint Diseases,<br />
Cardiovascular Diseases, Infectious Diseases, Metabolic Diseases, Oncology<br />
Daiichi Sankyo Europe GmbH's R&D activities centre around a permanent<br />
increase of our broad product line, with focus on the priority fields:<br />
Cardiovascular diseases Carbohydrate metabolic diseases Bone and joint<br />
diseases Immunological and allergic diseases Cancer Infectious diseases<br />
Daiichi Sankyo Europe GmbH is recognised for being among the leading pharmaceutical<br />
companies with the broadest spectrum of products affecting the<br />
atherosclerosis continuum:<br />
Olmesartan (A-II receptor blocker), Pravastatin (HMG-CoA reductase inhibitor),<br />
CS 505 (Pactimibe, ACAT inhibitor, phase II), CS 011 (antidiabetic, Glitazone,<br />
phase II), CS 917 (antidiabetic, gluconeogenesis inhibitor, phase II) and CS 747<br />
(Antiplatelet, ADP-receptor-antagonist, phase III). Daiichi Sankyo Europe GmbH's<br />
concerted research approach does ideally link our high R&D efforts to the benefits<br />
for doctors and patients.
Change language